Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Bausch + Lomb, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Bausch + Lomb, Inc.

Regulatory records
21
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 21 FDA records to the applicant name Bausch + Lomb, Inc.. The collection includes 1 510(k) clearance. It includes 3 original PMA approvals. 2 entries are PMA supplements. 15 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jan 17, 1992 to Oct 23, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code HQL appears in 11 of the 21 linked filings. The collection spans 4 FDA product codes and 3 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P240005, with 8 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 12 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 50 Technology Dr., Irvine, CA, 92618. Recorded on P910056/S067, decision dated Oct 23, 2026.

Changes described in PMA records

P910056/S067: enVista Hydrophobic Acrylic Intraocular Lens

Bausch & Lomb, Inc. submitted a 30-day notice for PMA supplement P910056/S067, decided OK30 on 2026-10-23. The stated purpose is a lidstock change for the enVista Hydrophobic Acrylic Intraocular Lens and enVista Envy Hydrophobic Acrylic Intraocular Lens, limited to non-preloaded models.

The supplement type is a 30-Day Notice, and the supplement reason is a process change involving manufacturer, sterilizer, packager, or supplier. The device category is intraocular lens, product code HQL, specialty ophthalmic. The notice does not state which lidstock material, supplier, or packaging configuration changed, nor does it provide safety or effectiveness data.

FDA approval-order wording

lidstock change for enVista Hydrophobic Acrylic Intraocular Lens & enVista Envy Hydrophobic Acrylic Intraocular Lens non-preloaded models

Oct 23, 2026 · 30-Day Notice

P240005/S010: enVista Envy Hydrophobic Acrylic Intraocular Lens

FDA recorded a 30-Day Notice decision, OK30, dated 2026-10-23 for P240005/S010, a supplement to Bausch & Lomb, Inc.'s enVista Envy Hydrophobic Acrylic Intraocular Lens. The listed device category is Lens, multifocal intraocular, with Ophthalmic specialty and product code MFK. The supplement type is 30-Day Notice and the recorded reason is Process Change - Manufacturer/Sterilizer/Packager/Supplier.

The recorded statement covers a lidstock change for the enVista Hydrophobic Acrylic Intraocular Lens and the enVista Envy Hydrophobic Acrylic Intraocular Lens, non-preloaded models. This describes a packaging-material change within the existing PMA rather than a new approval of the lens system. The source record includes no documents, so the specific lidstock materials, any testing performed and the basis for the OK30 decision are not available here.

Whether the change affects sterility assurance or shelf-life claims cannot be determined from the record, and no clinical or labeling conclusions are drawn.

FDA approval-order wording

lidstock change for enVista Hydrophobic Acrylic Intraocular Lens & enVista Envy Hydrophobic Acrylic Intraocular Lens non-preloaded models

Oct 23, 2026 · 30-Day Notice

P240005/S009: enVista Envy Hydrophobic Acrylic Intraocular Lens

The FDA database lists P240005/S009 as a 30-day notice for Bausch & Lomb's enVista Envy hydrophobic acrylic intraocular lens (product code MFK, multifocal intraocular lens). The supplement reason is recorded as a process change involving the manufacturer, sterilizer, packager or supplier. The stated scope was increasing the production lot size and extending the unrefrigerated holding time.

The S009 identifier ties the notice to PMA P240005, but a supplement is not a new approval of the whole lens system, and this manufacturing notice is not the original PMA. The statement is reported purpose only, not independent proof of safety or clinical effectiveness. It gives no lot-size figures, holding-time limits, process details or supporting data, so those specifics remain absent. No new indication or clinical use is established here.

FDA approval-order wording

increasing the production lot size and extending the unrefrigerated holding time

Oct 14, 2026 · 30-Day Notice

P910056/S066: enVista Hydrophobic Acrylic Intraocular Lens

The FDA record P910056/S066 for the enVista Hydrophobic Acrylic Intraocular Lens lists an OK30 decision dated 2026-10-14 under a 30-Day Notice. The supplement reason is a process change covering manufacturer, sterilizer, packager or supplier, and the stated change is increasing the production lot size and extending the unrefrigerated holding time. The notice does not name the affected manufacturing site, the prior and proposed lot sizes, or the previous and new holding durations.

The identifier ties the notice to PMA P910056 as supplement S066. An OK30 action on a 30-day notice is not an approval of the original PMA or of the whole lens system, and the source statement's reported purpose is not independent proof of safety or clinical effectiveness. The record carries no new indication, clinical data or performance result, and none should be inferred.

FDA approval-order wording

increasing the production lot size and extending the unrefrigerated holding time

Oct 14, 2026 · 30-Day Notice

P910056/S064: enVista Hydrophobic Acrylic Intraocular Lens

The FDA record P910056/S064 is a 30-Day Notice supplement for the enVista Hydrophobic Acrylic Intraocular Lens (product code HQL, Ophthalmic) from Bausch & Lomb, Inc., with a decision listed as OK30 and a decision date of 2026-09-30. The stated change is adding a new ISO Class 7 manufacturing cleanroom at the Clearwater, Florida facility; the record classifies this as a process change involving manufacturer, sterilizer, packager or supplier.

Because S064 is a supplement, it is not a new approval of the whole lens system, and a manufacturing notice is not an original PMA. The supplied record does not describe which lens models, packaging configurations, or production lines the added cleanroom supports, nor does it give room dimensions, qualification data, or FDA review findings. The statement reports an intended manufacturing purpose; it does not by itself establish safety or clinical effectiveness.

FDA approval-order wording

adding a new ISO Class 7 manufacturing cleanroom at the Clearwater Florida facility

Sep 30, 2026 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Bausch + Lomb, Inc.PMA supplementOct 23, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 23, 2026FDA
Bausch + Lomb, Inc.510(k) clearanceOct 16, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 14, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 14, 2026FDA
Bausch + Lomb, Inc.PMA supplementSep 30, 2026FDA
Bausch + Lomb, Inc.PMA supplementSep 30, 2026FDA
Bausch + Lomb, Inc.PMA supplementSep 29, 2026FDA
Bausch + Lomb, Inc.PMA supplementSep 3, 2026FDA
Bausch + Lomb, Inc.PMA supplementSep 3, 2026FDA
Bausch + Lomb, Inc.PMA supplementSep 3, 2026FDA
Bausch + Lomb, Inc.PMA supplementAug 12, 2026FDA
Bausch + Lomb, Inc.PMA supplementJul 22, 2026FDA
Bausch + Lomb, Inc.PMA supplementJul 22, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 24, 2025FDA
Bausch + Lomb, Inc.PMA supplementSep 30, 2025FDA
Bausch + Lomb, Inc.PMA supplementJul 30, 2025FDA
Bausch + Lomb, Inc.PMA supplementJul 22, 2025FDA
Bausch + Lomb, Inc.PMA approvalOct 10, 2024FDA
Bausch + Lomb, Inc.PMA approvalSep 5, 2008FDA
Bausch + Lomb, Inc.PMA approvalJan 17, 1992FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.